Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer

Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer is a phase 3, randomised interventional study registered as NCT06507371 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 170 participants, started 2024-07-29 and due to reach its primary completion in 2026-05-04. Interventions recorded: node-sparing modified short-course radiotherapy; PD-1 antibody; Capecitabine; Oxaliplatin; standard short-course radiotherapy. Conditions listed: Rectal Cancer. Primary outcome: pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: "Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clinical stage is cT3-4bN0/+M0, and the lymph nodes are limited to the mesorectum". Sites: China. No results are recorded here; the registry entry is the source.